Chiltern Partners with Karolinska Development - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Chiltern Partners with Karolinska Development

Source: Company News Release

Chiltern International Limited (Chiltern), a global contract research organization (CRO), proudly announces our partnership with Karolinska Development in Sweden, a life science investment company listed on NASDAQ OMX Stockholm (ticker: KDEV). Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations.

“We are extremely pleased to be selected as the partner CRO for Karolinska Development after an extensive CRO selection process in 2012. We were selected based on our compatibility with Karolinska Development’s specific development needs in terms of our global company infrastructure and our approach to deliver innovation, quality and flexibility to every project” stated Dr Jim Esinhart, CEO of Chiltern.

Aize Smink, Chiltern’s Chief Operating Officer, commented “We are honored and proud to be partnering with Karolinska Development, a world class organization committed to life science innovations and bringing novel therapies to market. A key aspect of our partnering is our early involvement in the development of studies and providing support services and consultation as needed in the product lifecycle. Together, we will work closely with the core team at Karolinska Development to achieve the goals and objectives of their pipeline.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here